TP53 and acute myeloid leukemia: A very recent study explored the frequency of the main driver gene mutations in a group of 325 Chinese AML patients of different ages, providing additional evidence that IDH2, TP53, RUNX1, and SF3B1 mutations have significantly higher incidences in 60 years and older AML patients compared to those with <60 years [56].